update pay ui
This commit is contained in:
@@ -1,477 +1,449 @@
|
||||
|
||||
<!DOCTYPE html>
|
||||
<html lang="zh-CN" data-theme="business">
|
||||
<html lang="zh-CN" data-theme="night">
|
||||
<head>
|
||||
<meta charset="UTF-8">
|
||||
<meta name="viewport" content="width=device-width, initial-scale=1.0">
|
||||
<title>禾元生物合作 - 稻米造血的千亿市场革命</title>
|
||||
<link href="https://cdn.jsdelivr.net/npm/daisyui@4.4.19/dist/full.min.css" rel="stylesheet" type="text/css" />
|
||||
<title>概念投研：禾元生物合作</title>
|
||||
<script src="https://cdn.tailwindcss.com"></script>
|
||||
<link href="https://cdn.jsdelivr.net/npm/remixicon@3.5.0/fonts/remixicon.css" rel="stylesheet">
|
||||
<script src="https://cdn.jsdelivr.net/npm/chart.js"></script>
|
||||
<link href="https://cdn.jsdelivr.net/npm/daisyui@4.10.1/dist/full.min.css" rel="stylesheet" type="text/css" />
|
||||
<script defer src="https://cdn.jsdelivr.net/npm/alpinejs@3.x.x/dist/cdn.min.js"></script>
|
||||
<link rel="preconnect" href="https://fonts.googleapis.com">
|
||||
<link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
|
||||
<link href="https://fonts.googleapis.com/css2?family=Inter:wght@300;400;500;700&family=Source+Code+Pro:wght@400;600&display=swap" rel="stylesheet">
|
||||
<style>
|
||||
@keyframes float {
|
||||
0%, 100% { transform: translateY(0px); }
|
||||
50% { transform: translateY(-20px); }
|
||||
body {
|
||||
background-color: #020418;
|
||||
color: #E0E0E0;
|
||||
font-family: 'Inter', sans-serif;
|
||||
overflow-x: hidden;
|
||||
}
|
||||
|
||||
.font-mono {
|
||||
font-family: 'Source Code Pro', monospace;
|
||||
}
|
||||
|
||||
.glow-effect-container {
|
||||
position: absolute;
|
||||
top: 0;
|
||||
left: 0;
|
||||
width: 100%;
|
||||
height: 100%;
|
||||
overflow: hidden;
|
||||
z-index: -1;
|
||||
}
|
||||
|
||||
.glow-sphere {
|
||||
position: absolute;
|
||||
border-radius: 50%;
|
||||
opacity: 0.15;
|
||||
filter: blur(150px);
|
||||
}
|
||||
|
||||
.glow-1 {
|
||||
background-color: #3b82f6; /* blue-500 */
|
||||
width: 600px;
|
||||
height: 600px;
|
||||
top: -150px;
|
||||
left: -150px;
|
||||
animation: pulse-glow 15s infinite alternate;
|
||||
}
|
||||
|
||||
.glow-2 {
|
||||
background-color: #8b5cf6; /* violet-500 */
|
||||
width: 700px;
|
||||
height: 700px;
|
||||
bottom: -200px;
|
||||
right: -200px;
|
||||
animation: pulse-glow 20s infinite alternate-reverse;
|
||||
}
|
||||
|
||||
@keyframes pulse-glow {
|
||||
0%, 100% { box-shadow: 0 0 20px rgba(34, 197, 94, 0.5); }
|
||||
50% { box-shadow: 0 0 40px rgba(34, 197, 94, 0.8); }
|
||||
from {
|
||||
transform: scale(0.9) translate(0, 0);
|
||||
}
|
||||
to {
|
||||
transform: scale(1.1) translate(20px, -20px);
|
||||
}
|
||||
}
|
||||
|
||||
.floating { animation: float 6s ease-in-out infinite; }
|
||||
.pulse-glow { animation: pulse-glow 2s ease-in-out infinite; }
|
||||
|
||||
.gradient-text {
|
||||
background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
|
||||
-webkit-background-clip: text;
|
||||
-webkit-text-fill-color: transparent;
|
||||
}
|
||||
|
||||
.glass-effect {
|
||||
background: rgba(255, 255, 255, 0.05);
|
||||
backdrop-filter: blur(10px);
|
||||
border: 1px solid rgba(255, 255, 255, 0.1);
|
||||
}
|
||||
|
||||
.timeline-line {
|
||||
background: linear-gradient(180deg, #3b82f6 0%, #8b5cf6 100%);
|
||||
}
|
||||
|
||||
.hero-gradient {
|
||||
background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
|
||||
}
|
||||
|
||||
.card-hover {
|
||||
.glass-card {
|
||||
background: rgba(15, 23, 42, 0.4);
|
||||
-webkit-backdrop-filter: blur(16px);
|
||||
backdrop-filter: blur(16px);
|
||||
border: 1px solid rgba(56, 189, 248, 0.2);
|
||||
border-radius: 24px;
|
||||
transition: all 0.3s ease;
|
||||
}
|
||||
|
||||
.card-hover:hover {
|
||||
transform: translateY(-5px);
|
||||
box-shadow: 0 20px 40px rgba(0,0,0,0.1);
|
||||
.glass-card:hover {
|
||||
box-shadow: 0 0 25px rgba(56, 189, 248, 0.2);
|
||||
border-color: rgba(56, 189, 248, 0.4);
|
||||
}
|
||||
|
||||
.stock-badge {
|
||||
animation: pulse-glow 3s ease-in-out infinite;
|
||||
.text-glow-cyan {
|
||||
color: #67e8f9;
|
||||
text-shadow: 0 0 8px rgba(103, 232, 249, 0.7);
|
||||
}
|
||||
|
||||
.text-glow-magenta {
|
||||
color: #f472b6;
|
||||
text-shadow: 0 0 8px rgba(244, 114, 182, 0.7);
|
||||
}
|
||||
|
||||
.number-animate {
|
||||
animation: countUp 2s ease-out;
|
||||
.section-title {
|
||||
font-size: 2.5rem;
|
||||
font-weight: bold;
|
||||
text-align: center;
|
||||
margin-bottom: 2.5rem;
|
||||
margin-top: 4rem;
|
||||
color: #fff;
|
||||
letter-spacing: 0.1em;
|
||||
text-transform: uppercase;
|
||||
position: relative;
|
||||
}
|
||||
|
||||
.section-title::after {
|
||||
content: '';
|
||||
position: absolute;
|
||||
bottom: -10px;
|
||||
left: 50%;
|
||||
transform: translateX(-50%);
|
||||
width: 100px;
|
||||
height: 2px;
|
||||
background: linear-gradient(90deg, transparent, #38bdf8, transparent);
|
||||
}
|
||||
|
||||
@keyframes countUp {
|
||||
from { opacity: 0; transform: translateY(20px); }
|
||||
to { opacity: 1; transform: translateY(0); }
|
||||
.card-title {
|
||||
color: #f0f9ff;
|
||||
font-weight: 700;
|
||||
font-size: 1.5rem;
|
||||
border-left: 4px solid #38bdf8;
|
||||
padding-left: 1rem;
|
||||
}
|
||||
|
||||
.market-card {
|
||||
background: linear-gradient(135deg, #f093fb 0%, #f5576c 100%);
|
||||
.timeline {
|
||||
position: relative;
|
||||
padding-left: 2rem;
|
||||
border-left: 2px solid rgba(56, 189, 248, 0.3);
|
||||
}
|
||||
.timeline-item {
|
||||
position: relative;
|
||||
margin-bottom: 2rem;
|
||||
}
|
||||
.timeline-item::before {
|
||||
content: '';
|
||||
position: absolute;
|
||||
left: -2.7rem;
|
||||
top: 4px;
|
||||
width: 16px;
|
||||
height: 16px;
|
||||
border-radius: 50%;
|
||||
background-color: #38bdf8;
|
||||
border: 3px solid #020418;
|
||||
box-shadow: 0 0 10px #38bdf8;
|
||||
}
|
||||
|
||||
.tech-card {
|
||||
background: linear-gradient(135deg, #4facfe 0%, #00f2fe 100%);
|
||||
.table {
|
||||
background-color: transparent;
|
||||
width: 100%;
|
||||
}
|
||||
.table thead th {
|
||||
color: #67e8f9;
|
||||
background-color: rgba(56, 189, 248, 0.1);
|
||||
border-bottom: 2px solid rgba(56, 189, 248, 0.3);
|
||||
}
|
||||
.table tbody tr {
|
||||
border-bottom: 1px solid rgba(56, 189, 248, 0.2);
|
||||
}
|
||||
.table tbody tr:last-child {
|
||||
border-bottom: none;
|
||||
}
|
||||
.table tbody tr:hover {
|
||||
background-color: rgba(56, 189, 248, 0.05);
|
||||
}
|
||||
.table a {
|
||||
color: #93c5fd;
|
||||
text-decoration: none;
|
||||
transition: color 0.2s;
|
||||
}
|
||||
.table a:hover {
|
||||
color: #60a5fa;
|
||||
text-decoration: underline;
|
||||
}
|
||||
|
||||
.policy-card {
|
||||
background: linear-gradient(135deg, #43e97b 0%, #38f9d7 100%);
|
||||
.bento-grid-item {
|
||||
display: flex;
|
||||
flex-direction: column;
|
||||
justify-content: center;
|
||||
padding: 1rem;
|
||||
}
|
||||
</style>
|
||||
</head>
|
||||
<body class="bg-gray-900 text-white">
|
||||
<!-- Hero Section -->
|
||||
<div class="hero-gradient min-h-screen flex items-center justify-center relative overflow-hidden">
|
||||
<div class="absolute inset-0 bg-black opacity-50"></div>
|
||||
<div class="container mx-auto px-4 relative z-10">
|
||||
<div class="text-center">
|
||||
<div class="floating mb-8">
|
||||
<div class="inline-flex items-center justify-center w-32 h-32 rounded-full bg-white bg-opacity-20 glass-effect">
|
||||
<i class="ri-plant-line text-6xl"></i>
|
||||
</div>
|
||||
</div>
|
||||
<h1 class="text-5xl md:text-7xl font-bold mb-6 gradient-text">禾元生物合作</h1>
|
||||
<p class="text-2xl md:text-3xl mb-4 text-white">稻米造血 · 千亿市场革命</p>
|
||||
<div class="flex flex-wrap justify-center gap-4 mb-8">
|
||||
<span class="badge badge-success badge-lg stock-badge">全球首创</span>
|
||||
<span class="badge badge-info badge-lg">科创板五套重启</span>
|
||||
<span class="badge badge-warning badge-lg">60%进口替代</span>
|
||||
</div>
|
||||
<div class="grid grid-cols-1 md:grid-cols-3 gap-6 max-w-4xl mx-auto">
|
||||
<div class="glass-effect rounded-xl p-6 number-animate">
|
||||
<div class="text-3xl font-bold text-green-400">300亿</div>
|
||||
<div class="text-sm text-gray-300">市场规模</div>
|
||||
</div>
|
||||
<div class="glass-effect rounded-xl p-6 number-animate" style="animation-delay: 0.2s">
|
||||
<div class="text-3xl font-bold text-blue-400">99.9999%</div>
|
||||
<div class="text-sm text-gray-300">产品纯度</div>
|
||||
</div>
|
||||
<div class="glass-effect rounded-xl p-6 number-animate" style="animation-delay: 0.4s">
|
||||
<div class="text-3xl font-bold text-purple-400">1/5</div>
|
||||
<div class="text-sm text-gray-300">传统成本</div>
|
||||
</div>
|
||||
</div>
|
||||
</div>
|
||||
</div>
|
||||
<div class="absolute bottom-10 left-1/2 transform -translate-x-1/2 animate-bounce">
|
||||
<i class="ri-arrow-down-line text-4xl text-white"></i>
|
||||
</div>
|
||||
<body class="min-h-screen">
|
||||
<div class="glow-effect-container">
|
||||
<div class="glow-sphere glow-1"></div>
|
||||
<div class="glow-sphere glow-2"></div>
|
||||
</div>
|
||||
|
||||
<!-- Core Logic Section -->
|
||||
<section class="py-20 px-4">
|
||||
<div class="container mx-auto">
|
||||
<h2 class="text-4xl font-bold text-center mb-16 gradient-text">核心驱动力</h2>
|
||||
<div class="grid grid-cols-1 md:grid-cols-3 gap-8">
|
||||
<div class="card card-hover bg-base-100 shadow-2xl">
|
||||
<div class="card-body">
|
||||
<div class="tech-card w-16 h-16 rounded-full flex items-center justify-center mb-4">
|
||||
<i class="ri-flask-line text-2xl text-white"></i>
|
||||
</div>
|
||||
<h3 class="card-title text-2xl mb-4">技术突破</h3>
|
||||
<p class="text-gray-300">全球首创"植物源重组蛋白表达平台"，利用水稻胚乳细胞作为生物工厂，实现99.9999%超高纯度，生产成本仅为传统血浆来源的五分之一。</p>
|
||||
<div class="mt-4">
|
||||
<div class="flex justify-between text-sm">
|
||||
<span>技术壁垒</span>
|
||||
<span class="text-blue-400">极高</span>
|
||||
</div>
|
||||
<div class="flex justify-between text-sm">
|
||||
<span>专利保护</span>
|
||||
<span class="text-green-400">完整</span>
|
||||
</div>
|
||||
</div>
|
||||
<div class="relative container mx-auto p-4 md:p-8">
|
||||
<header class="text-center mb-12 animate-fade-in-down">
|
||||
<h1 class="text-4xl md:text-6xl font-bold text-white tracking-wider text-glow-cyan">概念投研：禾元生物合作</h1>
|
||||
<p class="mt-4 text-sky-300 font-mono">北京价值前沿科技有限公司 AI投研agent：“价小前投研”</p>
|
||||
</header>
|
||||
|
||||
<div class="glass-card p-6 mb-12 max-w-4xl mx-auto">
|
||||
<p class="text-center text-slate-400"><strong>免责声明：</strong>本报告由AI合成数据生成，旨在提供信息参考，不构成任何投资建议。市场有风险，投资需谨慎。所有数据和分析请以相关公司官方公告为准。</p>
|
||||
</div>
|
||||
|
||||
<div class="grid grid-cols-12 gap-6">
|
||||
|
||||
<div class="col-span-12 xl:col-span-8 glass-card p-8">
|
||||
<h2 class="card-title text-glow-cyan mb-6">核心观点摘要</h2>
|
||||
<p class="text-lg text-slate-200 leading-relaxed">
|
||||
“禾元生物合作”概念的本质，是市场对一个**颠覆性技术平台商业化落地**的价值发现过程。其核心驱动力源于**“技术突破（全球首创产品获批）”**与**“政策东风（IPO标准重启）”**的双重共振。当前概念正从早期的主题炒作，向验证其商业化能力的**基本面驱动阶段**过渡，其未来潜力不仅在于首款产品的直接销售，更在于其底层技术平台作为**“赋能者”**（如提供高端药用辅料）向产业链延伸的巨大想象空间。
|
||||
</p>
|
||||
</div>
|
||||
|
||||
<div class="col-span-12 xl:col-span-4 glass-card p-6">
|
||||
<h2 class="card-title text-glow-magenta mb-6">关键事件时间轴</h2>
|
||||
<div class="timeline">
|
||||
<div class="timeline-item">
|
||||
<p class="font-semibold text-sky-300">2025年7月18日</p>
|
||||
<p class="text-sm text-slate-300">核心产品HY1001 (奥福民®) 获批上市，成为全球首个植物源重组人血清白蛋白药物。</p>
|
||||
</div>
|
||||
<div class="timeline-item">
|
||||
<p class="font-semibold text-sky-300">2025年7月1日</p>
|
||||
<p class="text-sm text-slate-300">科创板IPO成功过会，成“第五套标准”重启后第一股。</p>
|
||||
</div>
|
||||
<div class="timeline-item">
|
||||
<p class="font-semibold text-sky-300">2022年</p>
|
||||
<p class="text-sm text-slate-300">贝达药业(300558)以3.85亿元认购Pre-IPO轮股份，持股7.47%。</p>
|
||||
</div>
|
||||
<div class="timeline-item">
|
||||
<p class="font-semibold text-sky-300">2020年12月</p>
|
||||
<p class="text-sm text-slate-300">卫光生物与禾元生物建立战略合作关系。</p>
|
||||
</div>
|
||||
</div>
|
||||
|
||||
<div class="card card-hover bg-base-100 shadow-2xl">
|
||||
<div class="card-body">
|
||||
<div class="market-card w-16 h-16 rounded-full flex items-center justify-center mb-4">
|
||||
<i class="ri-line-chart-line text-2xl text-white"></i>
|
||||
</div>
|
||||
<h3 class="card-title text-2xl mb-4">市场刚需</h3>
|
||||
<p class="text-gray-300">国内人血清白蛋白市场近300亿元，年需求量1000吨，其中60%依赖进口。肝硬化低白蛋白血症占整体市场规模约30%，存在巨大进口替代空间。</p>
|
||||
<div class="mt-4">
|
||||
<div class="flex justify-between text-sm">
|
||||
<span>市场空间</span>
|
||||
<span class="text-purple-400">300亿+</span>
|
||||
</div>
|
||||
<div class="flex justify-between text-sm">
|
||||
<span>进口占比</span>
|
||||
<span class="text-orange-400">60%</span>
|
||||
</div>
|
||||
</div>
|
||||
</div>
|
||||
|
||||
<div class="col-span-12 glass-card p-8">
|
||||
<h2 class="card-title text-glow-cyan mb-6">概念核心逻辑与市场认知</h2>
|
||||
<div class="grid grid-cols-1 md:grid-cols-2 gap-8">
|
||||
<div>
|
||||
<h3 class="font-semibold text-lg text-sky-300 mb-2">核心驱动力</h3>
|
||||
<ul class="list-disc list-inside space-y-2 text-slate-300">
|
||||
<li><strong class="text-white">技术平台的颠覆性与稀缺性:</strong> 水稻胚乳细胞重组蛋白技术，规避血源制品病毒风险，产能不受血浆供应限制。</li>
|
||||
<li><strong class="text-white">里程碑式商业化突破:</strong> HY1001获批上市，将技术故事转化为商业现实。</li>
|
||||
<li><strong class="text-white">强烈的政策支持信号:</strong> 作为科创板第五套标准重启后首家过会企业，示范效应极强，提振板块信心。</li>
|
||||
</ul>
|
||||
</div>
|
||||
<div>
|
||||
<h3 class="font-semibold text-lg text-sky-300 mb-2">预期差分析</h3>
|
||||
<ul class="list-disc list-inside space-y-2 text-slate-300">
|
||||
<li><strong class="text-green-400">【积极预期差】商业模式广度被低估:</strong> 市场聚焦治疗性药物，但其作为高端药用辅料（ADC/CAR-T）的“赋能平台”价值认知尚不充分。</li>
|
||||
<li><strong class="text-red-400">【消极预期差】商业化周期长度被低估:</strong> 市场情绪亢奋，可能低估了从上市到盈利（预计2027年）长达2-3年“现金消耗期”的挑战和风险。</li>
|
||||
</ul>
|
||||
</div>
|
||||
</div>
|
||||
</div>
|
||||
|
||||
<div class="card card-hover bg-base-100 shadow-2xl">
|
||||
<div class="card-body">
|
||||
<div class="policy-card w-16 h-16 rounded-full flex items-center justify-center mb-4">
|
||||
<i class="ri-government-line text-2xl text-white"></i>
|
||||
</div>
|
||||
<h3 class="card-title text-2xl mb-4">政策红利</h3>
|
||||
<p class="text-gray-300">科创板第五套标准重启后首家IPO企业，获得资本市场对"硬科技"创新的支持。产品获批纳入优先审评审批程序，政策支持力度空前。</p>
|
||||
<div class="mt-4">
|
||||
<div class="flex justify-between text-sm">
|
||||
<span>政策支持</span>
|
||||
<span class="text-green-400">极强</span>
|
||||
<div class="col-span-12 glass-card p-8">
|
||||
<h2 class="card-title text-glow-magenta mb-6">关键催化剂与未来发展路径</h2>
|
||||
<div class="grid grid-cols-1 lg:grid-cols-2 gap-8">
|
||||
<div>
|
||||
<h3 class="font-semibold text-lg text-pink-300 mb-3">近期催化剂 (未来3-6个月)</h3>
|
||||
<ul class="space-y-3">
|
||||
<li class="flex items-start"><span class="text-pink-400 mr-3 mt-1">▶</span> HY1001初步销售数据披露，验证商业化能力。</li>
|
||||
<li class="flex items-start"><span class="text-pink-400 mr-3 mt-1">▶</span> 产品进入国家或地方医保目录，决定放量速度。</li>
|
||||
<li class="flex items-start"><span class="text-pink-400 mr-3 mt-1">▶</span> 在研管线HI1002（儿童腹泻药）进入二期临床的进展。</li>
|
||||
</ul>
|
||||
</div>
|
||||
<div class="space-y-4">
|
||||
<h3 class="font-semibold text-lg text-pink-300 mb-3">长期发展路径</h3>
|
||||
<div class="flex flex-col space-y-3">
|
||||
<div class="p-4 bg-slate-900/50 rounded-lg border border-pink-500/30">
|
||||
<p class="font-bold text-white">第一阶段 (当前-2027年): 商业化验证期</p>
|
||||
<p class="text-sm text-slate-300">推动HY1001市场渗透，力争实现盈利。</p>
|
||||
</div>
|
||||
<div class="flex justify-between text-sm">
|
||||
<span>融资渠道</span>
|
||||
<span class="text-blue-400">畅通</span>
|
||||
<div class="p-4 bg-slate-900/50 rounded-lg border border-pink-500/30">
|
||||
<p class="font-bold text-white">第二阶段 (2027年-): 平台价值扩张期</p>
|
||||
<p class="text-sm text-slate-300">形成产品矩阵，并大力拓展高端药用辅料B2B业务。</p>
|
||||
</div>
|
||||
<div class="p-4 bg-slate-900/50 rounded-lg border border-pink-500/30">
|
||||
<p class="font-bold text-white">第三阶段 (远期): 技术平台国际化期</p>
|
||||
<p class="text-sm text-slate-300">通过BD授权或自主研发，成为全球植物源重组蛋白领导者。</p>
|
||||
</div>
|
||||
</div>
|
||||
</div>
|
||||
</div>
|
||||
</div>
|
||||
</div>
|
||||
</section>
|
||||
|
||||
<!-- Timeline Section -->
|
||||
<section class="py-20 px-4 bg-gray-800">
|
||||
<div class="container mx-auto">
|
||||
<h2 class="text-4xl font-bold text-center mb-16 gradient-text">关键时间轴</h2>
|
||||
<div class="relative">
|
||||
<div class="timeline-line absolute left-1/2 transform -translate-x-1/2 w-1 h-full"></div>
|
||||
<div class="space-y-12">
|
||||
<div class="flex items-center justify-center">
|
||||
<div class="w-5/12 text-right pr-8">
|
||||
<div class="glass-effect rounded-lg p-4">
|
||||
<div class="text-sm text-gray-400">2024年5月</div>
|
||||
<div class="text-xl font-bold">完成III期临床试验</div>
|
||||
<div class="text-sm text-gray-300 mt-2">疗效非劣于血浆来源产品</div>
|
||||
</div>
|
||||
</div>
|
||||
<div class="w-2/12 flex justify-center">
|
||||
<div class="w-4 h-4 bg-blue-500 rounded-full"></div>
|
||||
</div>
|
||||
<div class="w-5/12"></div>
|
||||
|
||||
<div class="col-span-12 glass-card p-8">
|
||||
<h2 class="card-title text-glow-cyan mb-6">产业链图谱与核心公司剖析</h2>
|
||||
<div class="grid grid-cols-1 md:grid-cols-3 gap-6 text-center">
|
||||
<div class="bento-grid-item bg-slate-900/50 rounded-xl border border-sky-500/30 p-4">
|
||||
<h4 class="font-bold text-xl text-sky-300 mb-2">上游：服务与设备商</h4>
|
||||
<p class="text-slate-300"><strong class="text-white">博济医药 (300404):</strong> CRO服务</p>
|
||||
<p class="text-slate-300"><strong class="text-white">楚天科技 (300358):</strong> 生产设备</p>
|
||||
<p class="mt-2 text-sm text-slate-400">“卖铲人”，风险较低，业绩确定性高。</p>
|
||||
</div>
|
||||
|
||||
<div class="flex items-center justify-center">
|
||||
<div class="w-5/12"></div>
|
||||
<div class="w-2/12 flex justify-center">
|
||||
<div class="w-4 h-4 bg-green-500 rounded-full"></div>
|
||||
</div>
|
||||
<div class="w-5/12 pl-8">
|
||||
<div class="glass-effect rounded-lg p-4">
|
||||
<div class="text-sm text-gray-400">2025年6月25日</div>
|
||||
<div class="text-xl font-bold">科创板第五套标准重启</div>
|
||||
<div class="text-sm text-gray-300 mt-2">禾元生物成为首家上会企业</div>
|
||||
</div>
|
||||
</div>
|
||||
<div class="bento-grid-item bg-slate-900/50 rounded-xl border-2 border-sky-400 p-4 transform scale-105 shadow-2xl shadow-sky-500/30">
|
||||
<h4 class="font-bold text-xl text-sky-200 mb-2">中游：技术与产品核心</h4>
|
||||
<p class="text-slate-200 text-lg"><strong class="text-white">禾元生物 (688765)</strong></p>
|
||||
<p class="text-slate-300">概念源头，拥有核心技术平台</p>
|
||||
<p class="mt-2 text-sm text-amber-400">风险与想象空间并存，商业化是关键。</p>
|
||||
</div>
|
||||
|
||||
<div class="flex items-center justify-center">
|
||||
<div class="w-5/12 text-right pr-8">
|
||||
<div class="glass-effect rounded-lg p-4">
|
||||
<div class="text-sm text-gray-400">2025年7月18日</div>
|
||||
<div class="text-xl font-bold">双重催化剂</div>
|
||||
<div class="text-sm text-gray-300 mt-2">产品获批 + IPO注册获批</div>
|
||||
</div>
|
||||
</div>
|
||||
<div class="w-2/12 flex justify-center">
|
||||
<div class="w-4 h-4 bg-purple-500 rounded-full"></div>
|
||||
</div>
|
||||
<div class="w-5/12"></div>
|
||||
<div class="bento-grid-item bg-slate-900/50 rounded-xl border border-sky-500/30 p-4">
|
||||
<h4 class="font-bold text-xl text-sky-300 mb-2">下游：商业化与投资方</h4>
|
||||
<p class="text-slate-300"><strong class="text-white">贝达药业 (300558):</strong> 股东+独家经销商</p>
|
||||
<p class="text-slate-300"><strong class="text-white">国药控股:</strong> 销售渠道</p>
|
||||
<p class="text-slate-300"><strong class="text-white">华熙生物 (688363):</strong> 财务投资</p>
|
||||
<p class="mt-2 text-sm text-slate-400">利益深度绑定，分享成长红利。</p>
|
||||
</div>
|
||||
</div>
|
||||
<div class="mt-6 p-4 bg-slate-900/50 rounded-lg border border-sky-500/30">
|
||||
<h4 class="font-semibold text-lg text-sky-300 mb-2">核心玩家对比</h4>
|
||||
<p class="text-slate-300"><strong class="text-white">最佳“影子股” - 贝达药业:</strong> 逻辑最纯粹，风险收益比更优。通过“股权投资+独家经销”双重模式深度绑定，既分享长期价值，又获得短期确定性收入。</p>
|
||||
<p class="text-slate-300 mt-2"><strong class="text-white">待验证 - 卫光生物:</strong> 2020年战略合作后，无实质性进展信息披露，关联逻辑较弱，其重要性可能被市场高估。</p>
|
||||
</div>
|
||||
</div>
|
||||
|
||||
<div class="flex items-center justify-center">
|
||||
<div class="w-5/12"></div>
|
||||
<div class="w-2/12 flex justify-center">
|
||||
<div class="w-4 h-4 bg-orange-500 rounded-full pulse-glow"></div>
|
||||
</div>
|
||||
<div class="w-5/12 pl-8">
|
||||
<div class="glass-effect rounded-lg p-4">
|
||||
<div class="text-sm text-gray-400">2025年10月28日</div>
|
||||
<div class="text-xl font-bold text-green-400">正式上市</div>
|
||||
<div class="text-sm text-gray-300 mt-2">首日盘中临停，市场热度极高</div>
|
||||
</div>
|
||||
</div>
|
||||
<div class="col-span-12 grid md:grid-cols-3 gap-6">
|
||||
<div class="glass-card p-6">
|
||||
<h3 class="card-title text-glow-magenta mb-4">新闻数据洞察</h3>
|
||||
<ul class="space-y-3 text-slate-300">
|
||||
<li><strong>博济医药:</strong> 提供全流程CRO服务，是产品获批的直接合作伙伴。</li>
|
||||
<li><strong>贝达药业:</strong> 存在多重合作关系，包括持股7.47%、获得产品区域独家经销权及战略合作权益，是利益最深度的绑定方。</li>
|
||||
</ul>
|
||||
</div>
|
||||
<div class="glass-card p-6">
|
||||
<h3 class="card-title text-glow-magenta mb-4">路演核心信息</h3>
|
||||
<ul class="space-y-3 text-slate-300">
|
||||
<li><strong>产品获批:</strong> HY1001于2025年7月18日获批上市，为国内首个同类药物。</li>
|
||||
<li><strong>财务预期:</strong> 公司预计到2027年实现盈利，显示了创新药企长周期的特点。</li>
|
||||
<li><strong>政策信号:</strong> 作为科创板第五套标准重启后首家过会企业，体现了政策对硬科技创新的支持。</li>
|
||||
</ul>
|
||||
</div>
|
||||
<div class="glass-card p-6">
|
||||
<h3 class="card-title text-glow-magenta mb-4">研报关键发现</h3>
|
||||
<ul class="space-y-3 text-slate-300">
|
||||
<li><strong>销售网络:</strong> 已与国药控股、贝达药业等签订经销协议，完成全国销售网络布局。</li>
|
||||
<li><strong>研发应用:</strong> 其重组人白蛋白作为药用辅料，已应用于泰尔康生物的ADC药物和成都优赛诺的CAR-T产品中，打开B2B业务想象空间。</li>
|
||||
</ul>
|
||||
</div>
|
||||
</div>
|
||||
|
||||
<div class="col-span-12 glass-card p-8">
|
||||
<h2 class="card-title text-red-400 mb-6">潜在风险与挑战</h2>
|
||||
<div class="grid grid-cols-1 md:grid-cols-2 lg:grid-cols-3 gap-6">
|
||||
<div class="p-4 bg-red-900/20 rounded-lg border border-red-500/30">
|
||||
<h4 class="font-bold text-red-300">商业化风险</h4>
|
||||
<p class="text-sm text-slate-300">当前最大风险。市场接受度、定价与医保准入、与传统血源产品竞争是三大核心挑战。</p>
|
||||
</div>
|
||||
<div class="p-4 bg-red-900/20 rounded-lg border border-red-500/30">
|
||||
<h4 class="font-bold text-red-300">生产与成本风险</h4>
|
||||
<p class="text-sm text-slate-300">年产120吨新基地的规模化生产稳定性、良率和成本控制是关键，现有数据未提供详细信息。</p>
|
||||
</div>
|
||||
<div class="p-4 bg-red-900/20 rounded-lg border border-red-500/30">
|
||||
<h4 class="font-bold text-red-300">信息交叉验证风险</h4>
|
||||
<p class="text-sm text-slate-300">卫光生物的合作关系缺乏后续信息支撑，是唯一存在信息断层的地方，其关联度可能被高估。</p>
|
||||
</div>
|
||||
</div>
|
||||
</div>
|
||||
</div>
|
||||
</section>
|
||||
|
||||
<!-- Stock Data Table Section -->
|
||||
<section class="py-20 px-4">
|
||||
<div class="container mx-auto">
|
||||
<h2 class="text-4xl font-bold text-center mb-16 gradient-text">产业链核心公司</h2>
|
||||
<div class="overflow-x-auto">
|
||||
<table class="table table-zebra w-full bg-base-100 rounded-lg shadow-2xl">
|
||||
<div class="col-span-12 glass-card p-8">
|
||||
<h2 class="card-title text-glow-cyan mb-6">综合结论与投资启示</h2>
|
||||
<div class="space-y-4">
|
||||
<p><strong class="text-white">阶段判断:</strong> 概念正处于从“主题驱动”向“基本面驱动”过渡的关键拐点。市场热情高涨，但基本面兑现尚需时日 (预计2027年盈利)，存在短期估值过高风险。</p>
|
||||
<p><strong class="text-white">最具投资价值的方向:</strong></p>
|
||||
<ul class="list-decimal list-inside pl-4 text-slate-300 space-y-2">
|
||||
<li><strong>平台本身 (禾元生物):</strong> 适合高风险偏好投资者，赌其平台技术成为行业标准。</li>
|
||||
<li><strong>深度绑定的产业伙伴 (贝达药业):</strong> 风险相对可控的最佳路径，享受“股权+销售”双重红利。</li>
|
||||
<li><strong>被低估的“赋能者”角色:</strong> 最值得关注的启示，作为高端药用辅料供应商，搭上整个中国创新药(ADC, CAR-T)发展的快车，增长确定性可能更高。</li>
|
||||
</ul>
|
||||
<p><strong class="text-white">需重点跟踪的关键指标:</strong></p>
|
||||
<p class="text-slate-300 font-mono text-sm">HY1001季度销售额 | 医保目录进展 | 新生产基地产能利用率与毛利率 | 在研管线临床进展 | 新增药用辅料合作协议。</p>
|
||||
</div>
|
||||
</div>
|
||||
|
||||
</div>
|
||||
|
||||
<section>
|
||||
<h2 class="section-title">核心关联公司概览</h2>
|
||||
<div class="overflow-x-auto glass-card p-4">
|
||||
<table class="table">
|
||||
<thead>
|
||||
<tr class="bg-gradient-to-r from-purple-600 to-blue-600 text-white">
|
||||
<th class="text-lg font-bold">公司</th>
|
||||
<th class="text-lg font-bold">关系类型</th>
|
||||
<th class="text-lg font-bold">合作细节</th>
|
||||
<th class="text-lg font-bold">投资价值</th>
|
||||
<tr>
|
||||
<th>股票名称</th>
|
||||
<th>股票代码</th>
|
||||
<th>关联原因</th>
|
||||
<th>标签</th>
|
||||
</tr>
|
||||
</thead>
|
||||
<tbody>
|
||||
<tr class="hover">
|
||||
<td>
|
||||
<div class="flex items-center space-x-3">
|
||||
<div class="w-10 h-10 bg-green-500 rounded-full flex items-center justify-center">
|
||||
<span class="font-bold text-white">禾</span>
|
||||
</div>
|
||||
<div>
|
||||
<div class="font-bold">禾元生物</div>
|
||||
<div class="text-sm text-gray-400">688765</div>
|
||||
</div>
|
||||
</div>
|
||||
</td>
|
||||
<td><span class="badge badge-primary">核心标的</span></td>
|
||||
<td>核心产品奥福民®获批上市，全球首创植物源重组人血清白蛋白</td>
|
||||
<td><span class="text-red-400">⚡ 高风险高收益</span></td>
|
||||
</tr>
|
||||
<tr class="hover">
|
||||
<td>
|
||||
<div class="flex items-center space-x-3">
|
||||
<div class="w-10 h-10 bg-blue-500 rounded-full flex items-center justify-center">
|
||||
<span class="font-bold text-white">贝</span>
|
||||
</div>
|
||||
<div>
|
||||
<div class="font-bold">贝达药业</div>
|
||||
<div class="text-sm text-gray-400">300558</div>
|
||||
</div>
|
||||
</div>
|
||||
</td>
|
||||
<td><span class="badge badge-warning">投资+经销</span></td>
|
||||
<td>持股7.47%，获区域独家经销权，利用成熟销售网络推广</td>
|
||||
<td><span class="text-green-400">💎 稳健优选</span></td>
|
||||
</tr>
|
||||
<tr class="hover">
|
||||
<td>
|
||||
<div class="flex items-center space-x-3">
|
||||
<div class="w-10 h-10 bg-purple-500 rounded-full flex items-center justify-center">
|
||||
<span class="font-bold text-white">博</span>
|
||||
</div>
|
||||
<div>
|
||||
<div class="font-bold">博济医药</div>
|
||||
<div class="text-sm text-gray-400">300404</div>
|
||||
</div>
|
||||
</div>
|
||||
</td>
|
||||
<td><span class="badge badge-info">CRO服务</span></td>
|
||||
<td>提供三期临床研究服务，已赚取服务费</td>
|
||||
<td><span class="text-yellow-400">📊 事件驱动</span></td>
|
||||
</tr>
|
||||
<tr class="hover">
|
||||
<td>
|
||||
<div class="flex items-center space-x-3">
|
||||
<div class="w-10 h-10 bg-orange-500 rounded-full flex items-center justify-center">
|
||||
<span class="font-bold text-white">楚</span>
|
||||
</div>
|
||||
<div>
|
||||
<div class="font-bold">楚天科技</div>
|
||||
<div class="text-sm text-gray-400">300358</div>
|
||||
</div>
|
||||
</div>
|
||||
</td>
|
||||
<td><span class="badge badge-success">设备供应</span></td>
|
||||
<td>提供层析柱、超滤系统等关键生产设备</td>
|
||||
<td><span class="text-gray-400">🔧 产业配套</span></td>
|
||||
</tr>
|
||||
<tr class="hover">
|
||||
<td>
|
||||
<div class="flex items-center space-x-3">
|
||||
<div class="w-10 h-10 bg-red-500 rounded-full flex items-center justify-center">
|
||||
<span class="font-bold text-white">卫</span>
|
||||
</div>
|
||||
<div>
|
||||
<div class="font-bold">卫光生物</div>
|
||||
<div class="text-sm text-gray-400">002880</div>
|
||||
</div>
|
||||
</div>
|
||||
</td>
|
||||
<td><span class="badge badge-secondary">战略合作</span></td>
|
||||
<td>在重组生物制品领域建立战略合作，潜在竞争/合作者</td>
|
||||
<td><span class="text-orange-400">🔄 观望跟踪</span></td>
|
||||
</tr>
|
||||
<tr><td>禾元生物</td><td><a href="https://valuefrontier.cn/company?scode=688765" target="_blank">688765</a></td><td>重组人白蛋白注射液（奥福民®）已于2024年7月18日获批上市，成为全球首个植物源重组人血清白蛋白药物。</td><td>核心标的</td></tr>
|
||||
<tr><td>贝达药业</td><td><a href="https://valuefrontier.cn/company?scode=300558" target="_blank">300558</a></td><td>持股7.47%，并签署独家经销协议，是深度绑定的战略合作伙伴。</td><td>股权相关, 业务合作</td></tr>
|
||||
<tr><td>博济医药</td><td><a href="https://valuefrontier.cn/company?scode=300404" target="_blank">300404</a></td><td>为禾元生物的重组人白蛋白注射液提供三期临床研究CRO服务。</td><td>业务合作</td></tr>
|
||||
<tr><td>楚天科技</td><td><a href="https://valuefrontier.cn/company?scode=300358" target="_blank">300358</a></td><td>提供几十套层析柱及超滤系统等核心生产设备。</td><td>上游供应</td></tr>
|
||||
<tr><td>华熙生物</td><td><a href="https://valuefrontier.cn/company?scode=688363" target="_blank">688363</a></td><td>以29.06元/股参与禾元生物战略配售，获配0.77%发行股份。</td><td>股权相关</td></tr>
|
||||
<tr><td>双良节能</td><td><a href="https://valuefrontier.cn/company?scode=600481" target="_blank">600481</a></td><td>通过旗下子公司双良投资持有禾元生物0.1003%股份。</td><td>股权相关</td></tr>
|
||||
<tr><td>骆驼股份</td><td><a href="https://valuefrontier.cn/company?scode=601311" target="_blank">601311</a></td><td>作为有限合伙企业的合伙人，间接持有禾元生物股份。</td><td>股权相关</td></tr>
|
||||
<tr><td>富邦科技</td><td><a href="https://valuefrontier.cn/company?scode=300387" target="_blank">300387</a></td><td>通过富邦高投基金间接持股禾元生物。</td><td>股权相关</td></tr>
|
||||
<tr><td>卫光生物</td><td><a href="https://valuefrontier.cn/company?scode=002880" target="_blank">002880</a></td><td>2020年12月建立战略合作关系，但后续无实质进展披露。</td><td>业务合作 (待验证)</td></tr>
|
||||
</tbody>
|
||||
</table>
|
||||
</div>
|
||||
</div>
|
||||
</section>
|
||||
</section>
|
||||
|
||||
<section>
|
||||
<h2 class="section-title">相关个股涨幅归因分析</h2>
|
||||
<div class="space-y-4" x-data="{ active: '' }">
|
||||
|
||||
<div class="glass-card">
|
||||
<div class="p-4 cursor-pointer flex justify-between items-center" @click="active = active === '300858' ? '' : '300858'">
|
||||
<h3 class="text-lg font-semibold text-sky-300">科拓生物 (300858) - 涨幅归因</h3>
|
||||
<span class="text-sky-300 transition-transform" :class="{'rotate-90': active === '300858'}">➔</span>
|
||||
</div>
|
||||
<div x-show="active === '300858'" x-collapse>
|
||||
<div class="p-6 border-t border-sky-500/20 prose prose-invert max-w-none text-slate-300">
|
||||
<p><strong>核心催化剂：</strong>禾元生物IPO过会带动创新药板块整体走强。这一事件被市场解读为监管层对创新药企业的支持，疏通了生物医药投融资渠道，提振了板块情绪。</p>
|
||||
<p><strong>关联性：</strong>科拓生物自身在益生菌新药项目上有布局，并采用基因编辑、生物合成等先进技术开发新型药物，受益于创新药政策的外溢效应。</p>
|
||||
<p><strong>结论：</strong>上涨是短期事件催化（禾元生物IPO）和公司长期价值（创新药布局）共同作用的结果，反映了板块联动效应。</p>
|
||||
</div>
|
||||
</div>
|
||||
</div>
|
||||
|
||||
<!-- Catalysts & Risks Section -->
|
||||
<section class="py-20 px-4 bg-gray-800">
|
||||
<div class="container mx-auto">
|
||||
<div class="grid grid-cols-1 lg:grid-cols-2 gap-12">
|
||||
<div>
|
||||
<h2 class="text-3xl font-bold mb-8 gradient-text">近期催化剂</h2>
|
||||
<div class="space-y-4">
|
||||
<div class="glass-effect rounded-lg p-6 border-l-4 border-green-500">
|
||||
<h3 class="text-xl font-bold mb-2">📊 季度销售数据</h3>
|
||||
<p class="text-gray-300">首个完整销售季度的收入数据将直接验证商业化能力</p>
|
||||
</div>
|
||||
<div class="glass-effect rounded-lg p-6 border-l-4 border-blue-500">
|
||||
<h3 class="text-xl font-bold mb-2">🏭 产能释放进展</h3>
|
||||
<p class="text-gray-300">100万支工厂产能利用率和1200万支新基地建设进度</p>
|
||||
</div>
|
||||
<div class="glass-effect rounded-lg p-6 border-l-4 border-purple-500">
|
||||
<h3 class="text-xl font-bold mb-2">💊 新适应症拓展</h3>
|
||||
<p class="text-gray-300">严重烧伤、重症脓毒血症等适应症的临床进展</p>
|
||||
<div class="glass-card">
|
||||
<div class="p-4 cursor-pointer flex justify-between items-center" @click="active = active === '688117' ? '' : '688117'">
|
||||
<h3 class="text-lg font-semibold text-sky-300">圣诺生物 (688117) - 涨幅归因</h3>
|
||||
<span class="text-sky-300 transition-transform" :class="{'rotate-90': active === '688117'}">➔</span>
|
||||
</div>
|
||||
<div x-show="active === '688117'" x-collapse>
|
||||
<div class="p-6 border-t border-sky-500/20 prose prose-invert max-w-none text-slate-300">
|
||||
<p><strong>核心催化剂：</strong>科创板“第五套标准”重启及禾元生物的标杆性上市，极大地提振了整个科创板生物医药板块的投资信心和风险偏好。</p>
|
||||
<p><strong>关联性：</strong>圣诺生物与禾元生物同属科创板生物医药板块，直接受益于板块的整体估值联动和价值重估。其主营多肽药物CDMO业务也与“生物制造”主题高度契合。</p>
|
||||
<p><strong>结论：</strong>典型的“板块联动”和“事件驱动”性行情，在无自身利好催化下，受益于市场对科创板生物医药主题的追捧。</p>
|
||||
</div>
|
||||
</div>
|
||||
</div>
|
||||
<div>
|
||||
<h2 class="text-3xl font-bold mb-8 gradient-text">潜在风险</h2>
|
||||
<div class="space-y-4">
|
||||
<div class="glass-effect rounded-lg p-6 border-l-4 border-red-500">
|
||||
<h3 class="text-xl font-bold mb-2">⚠️ 商业化挑战</h3>
|
||||
<p class="text-gray-300">医生和患者对植物源产品的接受度需要时间培养</p>
|
||||
</div>
|
||||
<div class="glass-effect rounded-lg p-6 border-l-4 border-orange-500">
|
||||
<h3 class="text-xl font-bold mb-2">📉 盈利周期漫长</h3>
|
||||
<p class="text-gray-300">预计2027年才能实现盈利，短期财务压力较大</p>
|
||||
</div>
|
||||
<div class="glass-effect rounded-lg p-6 border-l-4 border-yellow-500">
|
||||
<h3 class="text-xl font-bold mb-2">🏛️ 政策风险</h3>
|
||||
<p class="text-gray-300">医保控费、集采等政策可能影响定价和利润空间</p>
|
||||
|
||||
<div class="glass-card">
|
||||
<div class="p-4 cursor-pointer flex justify-between items-center" @click="active = active === '920089' ? '' : '920089'">
|
||||
<h3 class="text-lg font-semibold text-sky-300">禾昌聚合 (920089) - 涨幅归因</h3>
|
||||
<span class="text-sky-300 transition-transform" :class="{'rotate-90': active === '920089'}">➔</span>
|
||||
</div>
|
||||
<div x-show="active === '920089'" x-collapse>
|
||||
<div class="p-6 border-t border-sky-500/20 prose prose-invert max-w-none text-slate-300">
|
||||
<p><strong>核心驱动：</strong>强烈的概念联想与板块外溢效应。禾元生物上市后股价表现惊人，市场资金迅速寻找关联性强的“影子股”。</p>
|
||||
<p><strong>关联性：</strong>“禾昌聚合”与“禾元生物”在名称上高度相似（“禾”字辈），这种简单直接的关联成为短期投机性炒作的锚点。</p>
|
||||
<p><strong>结论：</strong>一次典型的A股市场“名字联想式”炒作，上涨并非基于公司基本面，而是由市场热点引发的短期投机行为。</p>
|
||||
</div>
|
||||
</div>
|
||||
</div>
|
||||
|
||||
</div>
|
||||
</div>
|
||||
</section>
|
||||
</section>
|
||||
|
||||
<!-- Investment Insights Section -->
|
||||
<section class="py-20 px-4">
|
||||
<div class="container mx-auto">
|
||||
<h2 class="text-4xl font-bold text-center mb-16 gradient-text">投资启示</h2>
|
||||
<div class="bg-gradient-to-r from-purple-900 to-blue-900 rounded-2xl p-8 md:p-12">
|
||||
<div class="grid grid-cols-1 md:grid-cols-3 gap-8">
|
||||
<div class="text-center">
|
||||
<div class="w-20 h-20 bg-red-500 rounded-full flex items-center justify-center mx-auto mb-4">
|
||||
<i class="ri-rocket-2-line text-3xl text-white"></i>
|
||||
</div>
|
||||
<h3 class="text-xl font-bold mb-2">高风险高收益</h3>
|
||||
<p class="text-sm text-gray-300">禾元生物本身，商业化成功将获得最大估值重塑</p>
|
||||
</div>
|
||||
<div class="text-center">
|
||||
<div class="w-20 h-20 bg-green-500 rounded-full flex items-center justify-center mx-auto mb-4">
|
||||
<i class="ri-shield-check-line text-3xl text-white"></i>
|
||||
</div>
|
||||
<h3 class="text-xl font-bold mb-2">稳健优选</h3>
|
||||
<p class="text-sm text-gray-300">贝达药业，兼具投资收益和业务协同双重逻辑</p>
|
||||
</div>
|
||||
<div class="text-center">
|
||||
<div class="w-20 h-20 bg-blue-500 rounded-full flex items-center justify-center mx-auto mb-4">
|
||||
<i class="ri-pulse-line text-3xl text-white"></i>
|
||||
</div>
|
||||
<h3 class="text-xl font-bold mb-2">事件驱动</h3>
|
||||
<p class="text-sm text-gray-300">博济医药等上游公司，短期交易性机会</p>
|
||||
</div>
|
||||
</div>
|
||||
<div class="mt-12 text-center">
|
||||
<div class="inline-flex items-center space-x-4 glass-effect rounded-full px-8 py-4">
|
||||
<i class="ri-lightbulb-line text-2xl text-yellow-400"></i>
|
||||
<span class="text-lg font-semibold">关键跟踪指标：奥福民®季度销售额、毛利率变化、新适应症进展</span>
|
||||
</div>
|
||||
</div>
|
||||
</div>
|
||||
</div>
|
||||
</section>
|
||||
|
||||
<!-- Footer -->
|
||||
<footer class="py-8 px-4 bg-gray-900 border-t border-gray-800">
|
||||
<div class="container mx-auto text-center">
|
||||
<p class="text-gray-400">© 2025 禾元生物合作概念分析 | 投资有风险，决策需谨慎</p>
|
||||
</div>
|
||||
</footer>
|
||||
|
||||
<script>
|
||||
// Add smooth scrolling
|
||||
document.querySelectorAll('a[href^="#"]').forEach(anchor => {
|
||||
anchor.addEventListener('click', function (e) {
|
||||
e.preventDefault();
|
||||
document.querySelector(this.getAttribute('href')).scrollIntoView({
|
||||
behavior: 'smooth'
|
||||
});
|
||||
});
|
||||
});
|
||||
|
||||
// Intersection Observer for animations
|
||||
const observerOptions = {
|
||||
threshold: 0.1,
|
||||
rootMargin: '0px 0px -50px 0px'
|
||||
};
|
||||
|
||||
const observer = new IntersectionObserver((entries) => {
|
||||
entries.forEach(entry => {
|
||||
if (entry.isIntersecting) {
|
||||
entry.target.style.opacity = '1';
|
||||
entry.target.style.transform = 'translateY(0)';
|
||||
}
|
||||
});
|
||||
}, observerOptions);
|
||||
|
||||
document.querySelectorAll('.card-hover').forEach(card => {
|
||||
card.style.opacity = '0';
|
||||
card.style.transform = 'translateY(20px)';
|
||||
card.style.transition = 'all 0.6s ease-out';
|
||||
observer.observe(card);
|
||||
});
|
||||
</script>
|
||||
</div>
|
||||
</body>
|
||||
</html>
|
||||
Reference in New Issue
Block a user